Serum autotaxin levels are associated with Graves' disease.


Journal

Endocrine journal
ISSN: 1348-4540
Titre abrégé: Endocr J
Pays: Japan
ID NLM: 9313485

Informations de publication

Date de publication:
28 May 2019
Historique:
pubmed: 1 3 2019
medline: 24 12 2019
entrez: 1 3 2019
Statut: ppublish

Résumé

Graves' Disease is a representative autoimmune thyroid disease that presents with hyperthyroidism. Emerging evidence has shown the involvement of lysophosphatidic acid (LPA) and its producing enzyme, autotaxin (ATX), in the pathogenesis of various diseases; among them, the involvement of the ATX/LPA axis in some immunological disturbances has been proposed. In this study, we investigated the association between serum ATX levels and Graves' disease. We measured the levels of serum total ATX and ATX isoforms (classical ATX and novel ATX) in patients with untreated Graves' disease, Graves' disease treated with anti-thyroid drugs, patients with subacute thyroiditis, silent thyroiditis, Plummer's disease, or Hashimoto's thyroiditis, and patients who had undergone a total thyroidectomy, as well as normal subjects. The serum total ATX and ATX isoform levels were higher in the patients with Graves' disease, compared with the levels in the healthy subjects and the patients with subacute thyroiditis. Treatment with anti-thyroid drugs significantly decreased the serum ATX levels. The serum ATX levels and the changes in serum ATX levels during treatment were moderately or strongly correlated with the serum concentrations or the changes in thyroid hormones. However, the administration of T3 or T4 did not increase the expression or serum levels of ATX in 3T3L1 adipocytes or wild-type mice. In conclusion, the serum ATX levels were higher in subjects with Graves' disease, possibly because of a mechanism that does not involve hyperthyroidism. These results suggest the possible involvement of the ATX/LPA axis in the pathogenesis of Graves' disease.

Identifiants

pubmed: 30814442
doi: 10.1507/endocrj.EJ18-0451
doi:

Substances chimiques

Antithyroid Agents 0
Triiodothyronine 06LU7C9H1V
Phosphoric Diester Hydrolases EC 3.1.4.-
alkylglycerophosphoethanolamine phosphodiesterase EC 3.1.4.39
Thyroxine Q51BO43MG4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-422

Auteurs

Takahiro Nojiri (T)

Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.

Makoto Kurano (M)

Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Osamu Araki (O)

Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Gunma, Japan.

Kazuki Nakawatari (K)

Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.

Masako Nishikawa (M)

Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Satoshi Shimamoto (S)

Bioscience Division, TOSOH Corporation, Kanagawa, Japan.

Koji Igarashi (K)

Bioscience Division, TOSOH Corporation, Kanagawa, Japan.

Kuniyuki Kano (K)

Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan.

Junken Aoki (J)

Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan.

Shinji Kihara (S)

Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.

Masami Murakami (M)

Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan.

Yutaka Yatomi (Y)

Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan.
Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH